Amphastar Pharmaceuticals (AMPH) Financials

$23.39 +0.65 (+2.86%)

Closing price 04:00 PM Eastern

Extended Trading

$23.39 0.00 (0.00%)

As of 04:20 PM Eastern

Annual Income Statements for Amphastar Pharmaceuticals

This table shows Amphastar Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-2.79	9.82	3.65	-5.74	49	1.40	62	91	138	160	98
Consolidated Net Income / (Loss)	-2.79	9.82	3.65	-6.66	47	1.10	63	91	138	160	98
Net Income / (Loss) Continuing Operations	-2.79	9.82	3.65	-6.66	47	1.10	63	91	138	160	98
Total Pre-Tax Income	-10	15	1.25	-9.93	60	4.64	84	116	171	190	124
Total Operating Income	-6.90	15	-1.27	-8.62	-0.04	11	70	107	197	205	140
Total Gross Profit	77	104	91	107	132	143	200	249	351	374	356
Total Revenue	252	255	240	295	322	350	438	499	644	732	720
Operating Revenue	252	255	240	295	322	350	438	499	644	732	720
Total Cost of Revenue	174	151	150	188	190	207	238	250	293	358	364
Operating Cost of Revenue	174	151	150	188	190	207	238	250	293	358	364
Total Operating Expenses	84	89	92	116	132	132	130	141	154	168	216
Selling, General & Admin Expense	42	42	44	50	50	50	51	45	52	57	86
Marketing Expense	5.47	5.47	6.46	8.16	13	15	17	22	29	38	44
Research & Development Expense	37	42	44	58	69	67	61	75	74	74	86
Total Other Income / (Expense), net	-3.47	-0.75	2.52	-1.30	60	-6.32	14	8.54	-26	-16	-17
Interest Expense	0.99	1.02	0.83	0.24	0.12	0.37	0.89	1.85	27	30	25
Interest & Investment Income	0.32	0.27	0.43	0.46	1.00	0.64	0.60	1.32	5.46	11	8.68
Other Income / (Expense), net	-2.79	0.01	2.92	-1.52	59	-6.59	15	9.07	-3.93	4.08	0.02
Income Tax Expense	-7.58	4.81	-2.40	-3.27	14	3.54	21	23	32	30	26
Other Gains / (Losses), net	-	-	-	-	-	0.00	-0.21	-1.18	-1.98	-0.57	0.00
Basic Earnings per Share	($0.06)	$0.22	$0.08	($0.12)	$1.04	$0.03	$1.30	$1.88	$2.85	$3.29	$2.10
Weighted Average Basic Shares Outstanding	44.96M	45.38M	46.11M	46.40M	46.98M	47.04M	47.78M	48.55M	48.27M	48.43M	46.74M
Diluted Earnings per Share	($0.06)	$0.21	$0.08	($0.12)	$0.98	$0.03	$1.25	$1.74	$2.60	$3.06	$2.03
Weighted Average Diluted Shares Outstanding	44.96M	47.50M	48.37M	46.40M	49.91M	49.12M	49.78M	52.43M	53.00M	52.06M	48.22M
Weighted Average Basic & Diluted Shares Outstanding	46.50M	45.80M	45.60M	46.79M	46.24M	47.43M	48.15M	47.90M	48.10M	47.65M	45.37M

This table shows Amphastar Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	26	49	36	43	38	40	38	25	31	17	24
Consolidated Net Income / (Loss)	26	49	36	43	38	40	38	25	31	17	24
Net Income / (Loss) Continuing Operations	26	49	36	43	38	40	38	25	31	17	24
Total Pre-Tax Income	33	64	41	48	50	48	44	31	39	22	32
Total Operating Income	37	73	54	48	55	57	45	37	42	25	36
Total Gross Profit	73	108	96	90	95	102	87	85	86	99	86
Total Revenue	146	181	178	172	182	191	187	171	174	192	183
Operating Revenue	146	181	178	172	182	191	187	171	174	192	183
Total Cost of Revenue	73	72	82	82	87	89	100	85	88	93	97
Operating Cost of Revenue	73	72	82	82	87	89	100	85	88	93	97
Total Operating Expenses	36	36	42	42	40	45	42	48	44	73	50
Selling, General & Admin Expense	12	13	13	16	13	15	13	16	14	39	16
Marketing Expense	6.72	6.41	8.62	9.37	9.01	9.00	10	12	10	12	10
Research & Development Expense	17	17	20	17	18	21	18	20	20	22	23
Total Other Income / (Expense), net	-4.09	-9.04	-13	-0.13	-4.97	-9.37	-1.18	-6.43	-2.85	-3.81	-3.69
Interest Expense	3.60	14	9.46	8.61	8.61	6.70	6.43	6.29	6.28	6.28	6.63
Interest & Investment Income	1.03	1.20	2.30	2.56	3.34	2.43	2.29	2.09	1.92	2.25	2.42
Other Income / (Expense), net	-1.52	3.46	-5.48	5.92	0.30	-5.09	2.95	-2.23	1.51	0.23	0.52
Income Tax Expense	6.38	14	4.67	4.13	12	7.25	6.00	5.58	8.31	4.16	7.49
Basic Earnings per Share	$0.54	$1.01	$0.76	$0.90	$0.77	$0.83	$0.79	$0.53	$0.66	$0.38	$0.53
Weighted Average Basic Shares Outstanding	48.40M	48.70M	48.27M	48.21M	48.91M	48.62M	48.43M	47.64M	46.95M	46.47M	46.74M
Diluted Earnings per Share	$0.49	$0.91	$0.70	$0.81	$0.73	$0.78	$0.74	$0.51	$0.64	$0.37	$0.51
Weighted Average Diluted Shares Outstanding	53.10M	53.92M	53.00M	53.01M	52.05M	51.86M	52.06M	49.89M	48.13M	47.68M	48.22M
Weighted Average Basic & Diluted Shares Outstanding	48.86M	47.91M	48.10M	48.90M	48.68M	48.08M	47.65M	47.14M	46.50M	45.95M	45.37M

This table details how cash moves in and out of Amphastar Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-1.75	6.28	-4.90	21	-13	19	32	30	-12	7.31	19
Net Cash From Operating Activities	11	39	39	38	42	57	98	89	184	213	156
Net Cash From Continuing Operating Activities	11	39	39	38	42	57	98	89	184	213	156
Net Income / (Loss) Continuing Operations	-2.79	9.82	3.65	-6.66	47	1.10	63	91	138	160	98
Consolidated Net Income / (Loss)	-2.79	9.82	3.65	-6.66	47	1.10	63	91	138	160	98
Depreciation Expense	11	12	13	15	17	20	22	24	25	28	32
Amortization Expense	1.94	2.52	2.86	1.99	4.05	4.69	4.56	4.93	28	35	35
Non-Cash Adjustments To Reconcile Net Income	13	16	15	18	18	19	5.68	17	31	22	30
Changes in Operating Assets and Liabilities, net	-13	-2.30	5.00	10	-44	12	2.26	-48	-38	-32	-38
Net Cash From Investing Activities	-17	-40	-37	-42	-51	-36	-29	-33	-649	-125	-70
Net Cash From Continuing Investing Activities	-17	-40	-37	-42	-51	-36	-29	-33	-649	-125	-70
Purchase of Property, Plant & Equipment	-16	-21	-35	-47	-42	-34	-27	-24	-38	-41	-35
Acquisitions	-	-12	-	0.00	-	-	0.00	0.00	-506	-129	-2.25
Purchase of Investments	-	-3.60	-5.65	-0.31	-8.82	-14	-17	-36	-145	-77	-119
Sale and/or Maturity of Investments	-	3.08	3.65	0.09	0.00	12	19	28	39	126	90
Other Investing Activities, net	-0.93	-5.13	-1.80	0.20	-0.16	-1.41	-2.61	-1.37	1.39	-4.12	-4.36
Net Cash From Financing Activities	2.24	7.14	-7.72	25	-3.78	-2.25	-37	-26	454	-81	-67
Net Cash From Continuing Financing Activities	2.24	7.14	-7.72	25	-3.78	-2.25	-37	-26	454	-81	-67
Repayment of Debt	-8.99	-15	-9.71	-5.71	-6.78	-8.40	-40	-2.19	-344	-9.08	-0.91
Repurchase of Common Equity	-9.87	-9.91	-31	-25	-22	-24	-29	-40	-58	-85	-76
Issuance of Debt	6.79	10	19	8.78	3.57	7.52	70	0.00	845	18	6.22
Issuance of Common Equity	14	22	14	47	22	23	16	16	11	0.00	2.86
Other Financing Activities, net	-	-	-	0.00	0.00	-0.11	-54	0.00	0.00	-4.85	0.00
Effect of Exchange Rate Changes	2.25	0.08	0.50	-0.27	-0.10	0.35	-0.22	-0.22	-0.28	-0.19	0.21
Cash Interest Paid	1.94	1.72	1.88	2.38	2.44	2.20	2.11	3.02	18	27	23
Cash Income Taxes Paid	0.15	3.40	4.88	0.34	5.72	3.41	8.10	44	49	40	23

This table details how cash moves in and out of Amphastar Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Change in Cash & Equivalents	-26	120	-127	57	-12	2.50	-41	31	4.91	29	-46
Net Cash From Operating Activities	55	64	24	55	69	60	29	35	36	53	33
Net Cash From Continuing Operating Activities	55	64	24	55	69	60	29	35	36	53	33
Net Income / (Loss) Continuing Operations	26	49	36	43	38	40	38	25	31	17	24
Consolidated Net Income / (Loss)	26	49	36	43	38	40	38	25	31	17	24
Depreciation Expense	5.87	6.44	6.65	6.82	6.96	7.22	7.26	7.37	8.35	7.86	8.07
Amortization Expense	4.34	12	10	9.28	9.63	7.96	8.13	8.60	8.73	8.79	8.78
Non-Cash Adjustments To Reconcile Net Income	10	2.05	11	3.29	5.94	12	1.24	11	6.01	6.58	6.68
Changes in Operating Assets and Liabilities, net	8.48	-5.74	-40	-7.27	8.64	-7.33	-26	-17	-19	12	-15
Net Cash From Investing Activities	-509	-31	-103	15	-70	-35	-36	10	-0.63	-20	-61
Net Cash From Continuing Investing Activities	-509	-31	-103	15	-70	-35	-36	10	-0.63	-20	-61
Purchase of Property, Plant & Equipment	-9.05	-10	-9.44	-8.79	-6.04	-14	-12	-11	-11	-5.35	-8.27
Purchase of Investments	-9.20	-33	-92	-23	-	-25	-29	-7.09	-8.53	-35	-68
Sale and/or Maturity of Investments	11	14	-0.18	47	66	5.26	7.48	28	23	23	16
Other Investing Activities, net	-0.59	4.00	-1.67	-0.96	-0.64	-1.06	-1.47	-0.02	-2.32	-1.59	-0.43
Net Cash From Financing Activities	428	87	-47	-14	-11	-23	-34	-15	-30	-4.35	-18
Net Cash From Continuing Financing Activities	428	87	-47	-14	-11	-23	-34	-15	-30	-4.35	-18
Repayment of Debt	-82	-211	-51	-0.35	-8.01	-0.63	-0.09	-0.46	-0.29	-0.05	-0.11
Repurchase of Common Equity	-0.13	-50	-	0.00	-8.50	-35	-42	-11	-39	-4.85	-21
Issuance of Debt	500	345	-	4.08	-0.03	9.51	4.87	1.64	4.13	0.17	0.27
Issuance of Common Equity	-	2.13	3.56	-	-	-	-	-	-	0.38	1.98
Effect of Exchange Rate Changes	-0.02	-0.04	-0.24	-0.10	-0.02	-0.06	-0.01	0.12	0.14	-0.04	-0.01
Cash Interest Paid	1.53	9.33	5.48	8.63	5.23	8.53	4.42	7.58	4.09	7.47	4.08
Cash Income Taxes Paid	0.99	0.81	47	0.35	17	12	11	-0.90	23	0.01	0.40

This table presents Amphastar Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	390	428	451	514	587	631	672	742	1,513	1,577	1,629
Total Current Assets	176	184	188	220	255	280	318	378	490	534	636
Cash & Equivalents	66	72	66	86	74	93	126	156	144	152	170
Restricted Cash	1.29	1.39	4.16	4.16	4.16	4.07	2.44	2.44	2.44	2.44	2.44
Short-Term Investments	-	0.53	2.64	2.83	12	13	10	20	113	70	113
Accounts Receivable	33	27	36	52	45	66	79	89	115	136	144
Inventories, net	71	80	64	69	111	97	93	104	106	154	177
Prepaid Expenses	4.44	3.27	9.75	5.49	9.54	6.78	7.27	7.56	9.06	18	13
Other Current Assets	0.24	0.02	6.04	0.05	0.31	0.39	0.13	0.17	0.53	1.75	17
Plant, Property, & Equipment, net	142	153	181	210	234	260	244	238	283	297	311
Total Noncurrent Assets	72	91	83	83	98	91	109	125	741	746	683
Long-Term Investments	-	-	-	-	-	-	3.99	2.41	15	11	0.00
Noncurrent Note & Lease Receivables	-	-	-	-	0.89	0.61	0.35	0.75	0.56	0.38	0.22
Goodwill	40	50	45	42	41	41	39	37	613	591	566
Noncurrent Deferred & Refundable Income Taxes	27	31	29	31	26	25	22	39	53	71	42
Other Noncurrent Operating Assets	4.70	9.39	8.66	9.92	30	25	44	46	58	73	74
Total Liabilities & Shareholders' Equity	390	428	451	514	587	631	672	742	1,513	1,577	1,629
Total Liabilities	95	98	117	149	159	183	226	213	873	845	840
Total Current Liabilities	60	61	67	107	90	112	104	95	225	174	158
Short-Term Debt	11	5.37	6.31	18	7.74	12	2.20	3.05	0.44	0.23	1.64
Accounts Payable	14	48	58	87	77	96	90	84	93	157	148
Current Deferred & Payable Income Tax Liabilities	3.08	7.71	3.33	1.19	2.04	1.08	9.08	4.57	1.61	9.66	0.24
Other Current Liabilities	1.86	-	-	-	3.18	3.36	2.98	3.00	3.91	6.80	7.93
Total Noncurrent Liabilities	35	38	50	42	69	70	122	118	648	671	682
Long-Term Debt	30	32	41	32	39	34	75	73	590	602	609
Noncurrent Deferred Revenue	1.84	0.85	0.88	0.42	3.43	4.71	6.53	7.23	6.07	6.96	5.93
Other Noncurrent Operating Liabilities	2.67	3.21	7.06	8.94	26	31	40	38	52	63	68
Total Equity & Noncontrolling Interests	296	329	334	364	428	449	446	529	639	732	789
Total Preferred & Common Equity	296	329	334	332	381	402	446	529	639	732	789
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	296	329	334	332	381	402	446	529	639	732	789
Common Stock	248	283	314	344	367	410	422	455	486	505	535
Retained Earnings	60	71	73	67	116	118	180	272	409	569	667
Treasury Stock	-10	-20	-51	-75	-98	-122	-150	-190	-247	-333	-408
Accumulated Other Comprehensive Income / (Loss)	-2.48	-4.70	-2.10	-4.01	-4.69	-3.72	-6.77	-8.62	-8.48	-9.18	-5.31

This table presents Amphastar Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	6/30/2022	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025
Total Assets	724	727	774	1,378	1,545	1,574	1,492	1,545	1,626	1,615	1,666
Total Current Assets	377	384	408	385	543	555	483	546	588	581	639
Cash & Equivalents	166	157	177	149	267	201	190	192	183	188	216
Restricted Cash	2.44	2.44	2.44	4.89	6.46	2.44	2.44	2.44	2.44	2.44	2.44
Short-Term Investments	17	27	16	15	33	88	28	58	54	44	60
Accounts Receivable	81	77	101	105	119	138	131	140	145	133	147
Inventories, net	99	103	104	105	110	115	122	130	185	192	186
Prepaid Expenses	5.90	5.99	7.33	5.87	6.20	8.70	7.95	18	18	20	26
Other Current Assets	5.88	11	0.73	1.33	1.51	0.78	0.67	5.35	0.76	1.60	2.07
Plant, Property, & Equipment, net	238	233	243	279	281	289	288	295	308	310	309
Total Noncurrent Assets	109	110	123	715	721	731	721	704	731	724	718
Long-Term Investments	3.07	2.69	1.76	1.46	2.00	15	9.94	0.00	5.91	2.05	0.00
Noncurrent Note & Lease Receivables	0.20	0.60	0.71	0.66	0.61	0.52	0.47	0.43	0.34	0.30	0.26
Goodwill	38	37	37	626	619	607	601	595	585	578	572
Noncurrent Deferred & Refundable Income Taxes	22	22	39	41	41	53	53	53	71	71	71
Other Noncurrent Operating Assets	46	47	44	47	58	55	56	55	69	72	74
Total Liabilities & Shareholders' Equity	724	727	774	1,378	1,545	1,574	1,492	1,545	1,626	1,615	1,666
Total Liabilities	224	222	225	789	949	902	778	818	875	858	889
Total Current Liabilities	104	102	106	251	258	255	137	159	199	176	205
Short-Term Debt	2.06	1.68	2.17	13	0.43	0.43	0.25	0.25	0.22	0.93	0.92
Accounts Payable	98	96	89	218	223	117	131	153	176	167	191
Current Deferred & Payable Income Tax Liabilities	0.60	1.53	12	18	31	5.86	1.51	1.28	15	1.05	5.63
Other Current Liabilities	3.32	3.18	2.99	3.13	3.72	3.94	4.00	4.21	7.75	7.88	7.83
Total Noncurrent Liabilities	121	119	119	538	692	647	641	658	676	681	684
Long-Term Debt	74	74	73	488	638	594	587	596	604	608	609
Noncurrent Deferred Revenue	6.53	6.53	7.23	7.23	7.23	6.07	6.07	6.07	6.96	6.96	6.96
Other Noncurrent Operating Liabilities	40	39	39	42	46	47	48	56	65	67	69
Total Equity & Noncontrolling Interests	499	505	549	589	595	672	713	728	751	757	777
Total Preferred & Common Equity	499	505	549	589	595	672	713	728	751	757	777
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	499	505	549	589	595	672	713	728	751	757	777
Common Stock	443	449	457	471	478	476	488	496	509	521	527
Retained Earnings	222	238	298	324	373	452	490	531	594	625	642
Treasury Stock	-157	-171	-198	-197	-247	-247	-256	-291	-344	-383	-388
Accumulated Other Comprehensive Income / (Loss)	-8.71	-9.93	-8.27	-8.32	-8.41	-8.77	-8.83	-8.82	-7.97	-5.36	-5.27

This table displays calculated financial ratios and metrics derived from Amphastar Pharmaceuticals' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	45,952,174.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	45,952,174.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	2.13
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	19.51%	1.45%	-5.87%	22.69%	9.40%	8.53%	25.13%	13.98%	29.14%	13.59%	-1.65%
EBITDA Growth	206.78%	744.44%	-41.92%	-63.48%	1,161.89%	-63.28%	276.24%	30.70%	69.46%	10.76%	-24.11%
EBIT Growth	45.50%	258.73%	-89.27%	-714.48%	685.36%	-92.64%	1,832.32%	38.07%	65.62%	8.51%	-32.97%
NOPAT Growth	61.64%	313.74%	-135.90%	-62.90%	99.50%	8,705.51%	1,935.60%	62.55%	87.05%	8.05%	-35.71%
Net Income Growth	73.95%	452.35%	-62.86%	-282.62%	798.27%	-97.64%	5,670.37%	44.37%	50.51%	15.98%	-38.51%
EPS Growth	76.00%	450.00%	-61.90%	-250.00%	916.67%	-96.94%	4,066.67%	39.20%	49.43%	17.69%	-33.66%
Operating Cash Flow Growth	-49.26%	261.01%	1.68%	-2.60%	9.35%	37.12%	71.12%	-8.99%	105.76%	16.28%	-26.84%
Free Cash Flow Firm Growth	55.42%	26.38%	-48.51%	3.74%	-240.46%	103.52%	2,513.10%	-29.93%	-999.14%	107.88%	230.68%
Invested Capital Growth	5.08%	8.71%	5.40%	4.13%	19.89%	0.09%	-1.58%	11.74%	125.27%	15.09%	1.35%
Revenue Q/Q Growth	9.13%	-4.98%	-1.29%	11.04%	-1.92%	3.72%	6.05%	2.92%	7.16%	1.16%	-0.47%
EBITDA Q/Q Growth	127.67%	-32.98%	27.35%	50.83%	2.23%	-25.62%	50.49%	11.37%	7.25%	-0.63%	-4.83%
EBIT Q/Q Growth	63.59%	-50.08%	181.89%	14.88%	0.86%	-72.15%	79.99%	13.69%	3.92%	-0.19%	-7.86%
NOPAT Q/Q Growth	75.62%	-57.09%	-26.64%	28.64%	-102.16%	-45.60%	44.70%	18.48%	11.03%	-4.68%	-9.70%
Net Income Q/Q Growth	78.30%	-52.80%	844.29%	13.45%	-2.03%	-85.65%	67.69%	18.33%	1.67%	1.14%	-12.13%
EPS Q/Q Growth	79.31%	-53.33%	900.00%	14.29%	-6.67%	-76.92%	73.61%	16.00%	2.36%	1.32%	-10.18%
Operating Cash Flow Q/Q Growth	-45.83%	38.50%	-9.76%	-0.65%	-8.47%	24.42%	31.63%	-22.04%	4.94%	2.48%	2.52%
Free Cash Flow Firm Q/Q Growth	0.00%	35.37%	-219.01%	4.71%	-9.98%	118.53%	37.09%	-38.89%	4.80%	-18.44%	10.70%
Invested Capital Q/Q Growth	4.39%	-3.18%	0.98%	1.42%	2.36%	-1.96%	-1.89%	8.24%	3.19%	2.58%	0.57%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	30.75%	40.83%	37.68%	36.31%	40.92%	40.97%	45.63%	49.87%	54.49%	51.08%	49.46%
EBITDA Margin	1.42%	11.78%	7.27%	2.16%	24.96%	8.45%	25.40%	29.12%	38.21%	37.26%	28.75%
Operating Margin	-2.74%	6.03%	-0.53%	-2.93%	-0.01%	3.13%	15.96%	21.54%	30.57%	28.06%	19.50%
EBIT Margin	-3.85%	6.03%	0.69%	-3.44%	18.41%	1.25%	19.28%	23.36%	29.96%	28.62%	19.51%
Profit (Net Income) Margin	-1.11%	3.85%	1.52%	-2.26%	14.43%	0.31%	14.46%	18.31%	21.34%	21.79%	13.63%
Tax Burden Percent	26.89%	67.12%	291.99%	67.10%	77.21%	23.66%	75.23%	78.75%	80.27%	84.06%	79.35%
Interest Burden Percent	106.93%	95.10%	75.70%	97.90%	101.48%	106.13%	99.66%	99.55%	88.76%	90.58%	88.04%
Effective Tax Rate	0.00%	32.88%	-191.99%	0.00%	22.79%	76.34%	24.52%	20.23%	18.58%	15.64%	20.65%
Return on Invested Capital (ROIC)	-1.84%	3.67%	-1.23%	-1.92%	-0.01%	0.67%	13.79%	21.35%	23.26%	16.87%	10.07%
ROIC Less NNEP Spread (ROIC-NNEP)	-9.71%	5.27%	-25.04%	-0.09%	-108.88%	3.50%	-2.52%	14.75%	1.59%	12.83%	6.22%
Return on Net Nonoperating Assets (RNNOA)	0.87%	-0.53%	2.33%	0.01%	11.75%	-0.42%	0.36%	-2.59%	0.29%	6.38%	2.83%
Return on Equity (ROE)	-0.97%	3.14%	1.10%	-1.91%	11.75%	0.25%	14.16%	18.76%	23.55%	23.26%	12.90%
Cash Return on Invested Capital (CROIC)	-6.79%	-4.67%	-6.49%	-5.96%	-18.10%	0.58%	15.38%	10.26%	-53.76%	2.84%	8.73%
Operating Return on Assets (OROA)	-2.49%	3.76%	0.38%	-2.10%	10.79%	0.72%	12.96%	16.49%	17.12%	13.56%	8.76%
Return on Assets (ROA)	-0.72%	2.40%	0.83%	-1.38%	8.45%	0.18%	9.72%	12.93%	12.20%	10.32%	6.12%
Return on Common Equity (ROCE)	-0.97%	3.14%	1.10%	-1.82%	10.59%	0.22%	13.42%	18.76%	23.55%	23.26%	12.90%
Return on Equity Simple (ROE_SIMPLE)	-0.94%	2.98%	1.09%	-2.00%	12.19%	0.27%	14.21%	17.29%	21.51%	21.78%	0.00%
Net Operating Profit after Tax (NOPAT)	-4.83	10	-3.71	-6.04	-0.03	2.59	53	86	160	173	111
NOPAT Margin	-1.92%	4.04%	-1.54%	-2.05%	-0.01%	0.74%	12.05%	17.18%	24.89%	23.68%	15.48%
Net Nonoperating Expense Percent (NNEP)	7.87%	-1.59%	23.80%	-1.83%	108.87%	-2.83%	16.31%	6.60%	21.67%	4.04%	3.85%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	14.18%	13.05%	12.99%	7.96%
Cost of Revenue to Revenue	69.25%	59.17%	62.32%	63.69%	59.08%	59.03%	54.37%	50.13%	45.51%	48.92%	50.54%
SG&A Expenses to Revenue	16.50%	16.39%	18.51%	16.93%	15.60%	14.40%	11.75%	9.03%	8.00%	7.75%	11.94%
R&D to Revenue	14.82%	16.27%	18.11%	19.54%	21.36%	19.22%	13.92%	14.98%	11.44%	10.10%	11.92%
Operating Expenses to Revenue	33.49%	34.81%	38.21%	39.23%	40.94%	37.84%	29.66%	28.33%	23.92%	23.01%	29.96%
Earnings before Interest and Taxes (EBIT)	-9.69	15	1.65	-10	59	4.37	84	117	193	209	140
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	3.56	30	17	6.38	80	30	111	145	246	273	207
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	2.65	2.76	2.37	2.37	2.50	2.56	4.63	2.44	1.56
Price to Tangible Book Value (P/TBV)	0.00	0.00	3.07	3.16	2.66	2.64	2.74	2.76	113.41	12.60	5.52
Price to Revenue (P/Rev)	0.00	0.00	3.68	3.11	2.81	2.73	2.55	2.71	4.60	2.44	1.71
Price to Earnings (P/E)	0.00	0.00	242.55	0.00	18.50	680.90	17.94	14.82	21.54	11.19	12.55
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.41%	0.00%	5.41%	0.15%	5.57%	6.75%	4.64%	8.94%	7.97%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	2.79	2.82	2.36	2.43	2.76	2.95	3.43	1.96	1.40
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	3.58	3.08	2.82	2.68	2.39	2.50	5.09	2.94	2.16
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	49.22	142.10	11.30	31.76	9.43	8.60	13.32	7.89	7.52
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	520.82	0.00	15.32	214.81	12.42	10.72	16.98	10.27	11.08
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	362.15	19.87	14.57	20.44	12.42	13.96
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	21.92	23.73	21.77	16.39	10.70	14.01	17.87	10.09	9.97
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	416.84	17.82	30.31	0.00	73.71	16.11
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.14	0.11	0.14	0.14	0.11	0.10	0.17	0.14	0.92	0.82	0.77
Long-Term Debt to Equity	0.10	0.10	0.12	0.09	0.09	0.08	0.17	0.14	0.92	0.82	0.77
Financial Leverage	-0.09	-0.10	-0.09	-0.10	-0.11	-0.12	-0.14	-0.18	0.18	0.50	0.45
Leverage Ratio	1.35	1.31	1.33	1.38	1.39	1.39	1.46	1.45	1.93	2.25	2.11
Compound Leverage Factor	1.44	1.24	1.00	1.35	1.41	1.48	1.45	1.44	1.71	2.04	1.86
Debt to Total Capital	12.21%	10.28%	12.38%	12.11%	9.93%	9.38%	14.73%	12.55%	47.99%	45.11%	43.62%
Short-Term Debt to Total Capital	3.25%	1.46%	1.66%	4.40%	1.63%	2.48%	0.42%	0.50%	0.04%	0.02%	0.12%
Long-Term Debt to Total Capital	8.96%	8.82%	10.72%	7.71%	8.30%	6.90%	14.31%	12.05%	47.96%	45.09%	43.51%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	7.70%	9.73%	9.37%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	87.79%	89.72%	87.62%	80.19%	80.34%	81.25%	85.27%	87.45%	52.01%	54.89%	56.38%
Debt to EBITDA	11.54	1.25	2.70	7.87	0.59	1.57	0.69	0.52	2.40	2.21	2.95
Net Debt to EBITDA	-7.38	-1.22	-1.44	-6.76	-0.53	-2.14	-0.59	-0.72	1.28	1.34	1.57
Long-Term Debt to EBITDA	8.47	1.08	2.34	5.02	0.49	1.16	0.67	0.50	2.39	2.21	2.94
Debt to NOPAT	-8.51	3.66	-12.73	-8.32	-1,565.23	17.92	1.46	0.89	3.68	3.47	5.48
Net Debt to NOPAT	5.44	-3.54	6.81	7.14	1,407.33	-24.40	-1.25	-1.22	1.97	2.12	2.92
Long-Term Debt to NOPAT	-6.25	3.14	-11.02	-5.30	-1,308.17	13.19	1.42	0.85	3.68	3.47	5.46
Altman Z-Score	0.00	0.00	5.61	4.65	4.91	4.30	4.78	5.97	3.47	2.95	2.53
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	4.57%	9.86%	10.57%	5.19%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.93	3.04	2.79	2.06	2.84	2.49	3.06	3.99	2.17	3.07	4.02
Quick Ratio	1.66	1.64	1.55	1.32	1.45	1.53	2.08	2.79	1.65	2.06	2.70
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-18	-13	-20	-19	-64	2.25	59	41	-371	29	97
Operating Cash Flow to CapEx	66.77%	180.34%	111.71%	82.02%	100.50%	169.15%	356.91%	377.68%	480.80%	519.93%	447.55%
Free Cash Flow to Firm to Interest Expense	-18.08	-12.83	-23.62	-77.27	-537.22	6.02	66.48	22.33	-13.65	0.96	3.79
Operating Cash Flow to Interest Expense	10.82	37.66	47.47	157.16	350.94	153.12	110.73	48.31	6.76	7.03	6.13
Operating Cash Flow Less CapEx to Interest Expense	-5.39	16.78	4.98	-34.45	1.74	62.60	79.70	35.52	5.35	5.68	4.76
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.65	0.62	0.55	0.61	0.59	0.57	0.67	0.71	0.57	0.47	0.45
Accounts Receivable Turnover	8.97	8.50	7.65	6.68	6.61	6.28	6.05	5.95	6.33	5.83	5.14
Inventory Turnover	2.28	2.01	2.09	2.82	2.12	1.99	2.51	2.55	2.80	2.76	2.20
Fixed Asset Turnover	1.79	1.73	1.44	1.51	1.45	1.42	1.74	2.07	2.47	2.52	2.37
Accounts Payable Turnover	14.49	4.92	2.85	2.59	2.32	2.39	2.57	2.88	3.30	2.86	2.38
Days Sales Outstanding (DSO)	40.69	42.92	47.70	54.60	55.22	58.10	60.37	61.30	57.70	62.64	70.95
Days Inventory Outstanding (DIO)	160.31	181.84	174.81	129.26	172.33	183.23	145.40	143.29	130.32	132.28	165.85
Days Payable Outstanding (DPO)	25.18	74.25	128.16	140.97	157.62	152.50	141.88	126.80	110.52	127.62	153.19
Cash Conversion Cycle (CCC)	175.83	150.51	94.35	42.89	69.94	88.84	63.89	77.79	77.50	67.30	83.60
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	269	293	309	321	385	385	379	424	955	1,099	1,114
Invested Capital Turnover	0.96	0.91	0.80	0.94	0.91	0.91	1.14	1.24	0.93	0.71	0.65
Increase / (Decrease) in Invested Capital	13	23	16	13	64	0.34	-6.08	45	531	144	15
Enterprise Value (EV)	0.00	0.00	859	906	909	938	1,048	1,250	3,279	2,152	1,556
Market Capitalization	0.00	0.00	885	917	905	955	1,114	1,354	2,963	1,785	1,231
Book Value per Share	$6.57	$7.26	$7.26	$7.21	$8.12	$8.47	$9.31	$10.94	$13.35	$15.23	$17.17
Tangible Book Value per Share	$5.69	$6.15	$6.28	$6.29	$7.25	$7.61	$8.50	$10.17	$0.55	$2.95	$4.85
Total Capital	337	367	381	415	475	495	523	605	1,229	1,334	1,399
Total Debt	41	38	47	50	47	46	77	76	590	602	610
Total Long-Term Debt	30	32	41	32	39	34	75	73	590	602	609
Net Debt	-26	-37	-25	-43	-42	-63	-66	-105	316	367	325
Capital Expenditures (CapEx)	16	21	35	47	42	34	27	24	38	41	35
Debt-free, Cash-free Net Working Capital (DFCFNWC)	60	55	55	38	83	70	77	108	5.39	136	194
Debt-free Net Working Capital (DFNWC)	127	129	127	132	173	180	217	287	265	361	480
Net Working Capital (NWC)	116	123	121	114	165	167	214	283	264	360	478
Net Nonoperating Expense (NNE)	-2.04	0.50	-7.35	0.62	-47	1.49	-11	-5.64	23	14	13
Net Nonoperating Obligations (NNO)	-26	-37	-25	-43	-42	-63	-66	-105	316	367	325
Total Depreciation and Amortization (D&A)	13	15	16	17	21	25	27	29	53	63	67
Debt-free, Cash-free Net Working Capital to Revenue	23.68%	21.39%	22.70%	13.04%	25.89%	20.03%	17.68%	21.71%	0.84%	18.64%	26.98%
Debt-free Net Working Capital to Revenue	50.46%	50.49%	52.84%	44.71%	53.66%	51.38%	49.46%	57.42%	41.07%	49.26%	66.61%
Net Working Capital to Revenue	46.11%	48.39%	50.21%	38.52%	51.26%	47.87%	48.95%	56.81%	41.00%	49.23%	66.38%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.06)	$0.23	$0.10	($0.12)	$1.04	$0.03	$1.30	$1.88	$2.85	$3.29	$2.10
Adjusted Weighted Average Basic Shares Outstanding	44.96M	45.38M	46.11M	46.40M	46.98M	47.04M	47.78M	48.55M	48.27M	48.43M	46.74M
Adjusted Diluted Earnings per Share	($0.06)	$0.22	$0.09	($0.12)	$0.98	$0.03	$1.25	$1.74	$2.60	$3.06	$2.03
Adjusted Weighted Average Diluted Shares Outstanding	44.96M	47.50M	48.37M	46.40M	49.91M	49.12M	49.78M	52.43M	53.00M	52.06M	48.22M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	44.91M	45.91M	46.35M	46.79M	46.24M	47.43M	48.15M	47.90M	48.10M	47.65M	45.37M
Normalized Net Operating Profit after Tax (NOPAT)	-4.83	10	-2.74	-6.04	-0.03	7.67	53	86	160	173	111
Normalized NOPAT Margin	-1.92%	4.04%	-1.14%	-2.05%	-0.01%	2.19%	12.05%	17.18%	24.89%	23.68%	15.48%
Pre Tax Income Margin	-4.12%	5.73%	0.52%	-3.37%	18.68%	1.33%	19.22%	23.26%	26.59%	25.93%	17.17%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-9.82	15.02	2.00	-41.72	498.74	11.68	95.39	63.14	7.11	6.90	5.51
NOPAT to Interest Expense	-4.89	10.08	-4.49	-24.84	-0.25	6.93	59.61	46.45	5.91	5.71	4.37
EBIT Less CapEx to Interest Expense	-26.03	-5.86	-40.50	-233.34	149.54	-78.84	64.37	50.35	5.70	5.55	4.14
NOPAT Less CapEx to Interest Expense	-21.10	-10.80	-46.98	-216.46	-349.45	-83.59	28.58	33.66	4.50	4.36	3.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-353.96%	100.90%	843.08%	-376.08%	47.93%	2,226.53%	45.61%	43.67%	42.27%	53.57%	77.05%

This table displays calculated financial ratios and metrics derived from Amphastar Pharmaceuticals' official financial filings.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	45,952,174.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	45,952,174.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0.53
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	18.02%	50.30%	31.91%	22.72%	25.17%	5.90%	4.73%	-0.76%	-4.38%	0.33%	-1.83%
EBITDA Growth	50.27%	212.32%	34.26%	72.90%	58.14%	-29.29%	-2.63%	-27.13%	-15.70%	-37.13%	-16.55%
EBIT Growth	51.72%	233.48%	17.69%	63.21%	56.91%	-31.76%	-0.83%	-34.99%	-21.29%	-50.82%	-24.90%
NOPAT Growth	57.48%	243.70%	53.72%	64.26%	40.34%	-14.63%	-18.58%	-30.36%	-20.21%	-57.78%	-30.09%
Net Income Growth	50.61%	210.08%	6.65%	65.86%	45.26%	-17.86%	4.97%	-41.44%	-18.23%	-57.09%	-35.65%
EPS Growth	48.48%	203.33%	9.38%	62.00%	48.98%	-14.29%	5.71%	-37.04%	-12.33%	-52.56%	-31.08%
Operating Cash Flow Growth	1,851.08%	215.75%	56.73%	36.92%	25.83%	-6.80%	21.62%	-36.56%	-48.50%	-12.31%	13.23%
Free Cash Flow Firm Growth	-202,747.37%	-4,225.19%	-3,511.87%	-1,238.36%	78.68%	79.54%	78.24%	75.48%	75.54%	83.88%	111.79%
Invested Capital Growth	138.38%	136.30%	125.27%	124.99%	16.22%	15.78%	15.09%	15.68%	5.57%	3.37%	1.35%
Revenue Q/Q Growth	4.06%	23.91%	-1.36%	-3.52%	6.14%	4.84%	-2.45%	-8.58%	2.28%	9.99%	-4.55%
EBITDA Q/Q Growth	12.58%	108.25%	-31.33%	7.40%	2.96%	-6.89%	-5.43%	-19.62%	19.10%	-30.56%	25.52%
EBIT Q/Q Growth	7.07%	115.20%	-36.30%	11.20%	2.94%	-6.41%	-7.43%	-27.10%	24.63%	-41.52%	41.37%
NOPAT Q/Q Growth	11.27%	90.66%	-15.50%	-8.37%	-4.94%	15.98%	-19.40%	-21.63%	8.91%	-38.64%	33.47%
Net Income Q/Q Growth	0.35%	88.42%	-26.52%	19.38%	-12.11%	6.54%	-6.10%	-33.40%	22.72%	-44.09%	40.80%
EPS Q/Q Growth	-2.00%	85.71%	-23.08%	15.71%	-9.88%	6.85%	-5.13%	-31.08%	25.49%	-42.19%	37.84%
Operating Cash Flow Q/Q Growth	36.01%	17.13%	-62.91%	131.69%	24.99%	-13.24%	-51.60%	20.86%	1.47%	47.74%	-37.50%
Free Cash Flow Firm Q/Q Growth	-1,281.19%	5.50%	-1.26%	-1.25%	78.00%	9.29%	-7.66%	-14.10%	78.05%	40.24%	178.75%
Invested Capital Q/Q Growth	115.92%	0.49%	3.19%	0.49%	11.53%	0.11%	2.58%	1.01%	1.78%	-1.97%	0.57%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	49.92%	60.04%	53.98%	52.43%	52.18%	53.31%	46.45%	49.99%	49.59%	51.42%	46.79%
EBITDA Margin	31.29%	52.58%	36.61%	40.75%	39.53%	35.11%	34.03%	29.92%	34.85%	22.00%	28.93%
Operating Margin	25.32%	40.25%	30.31%	27.94%	30.27%	29.83%	24.20%	21.87%	24.19%	13.20%	19.45%
EBIT Margin	24.28%	42.17%	27.23%	31.39%	30.44%	27.17%	25.79%	20.56%	25.05%	13.32%	19.73%
Profit (Net Income) Margin	17.93%	27.26%	20.31%	25.13%	20.81%	21.14%	20.35%	14.83%	17.79%	9.04%	13.34%
Tax Burden Percent	79.63%	77.35%	87.48%	90.19%	75.53%	84.79%	86.36%	81.93%	78.89%	80.65%	76.55%
Interest Burden Percent	92.73%	83.58%	85.25%	88.77%	90.50%	91.78%	91.41%	88.03%	90.02%	84.20%	88.35%
Effective Tax Rate	19.46%	22.04%	11.30%	8.62%	24.47%	15.21%	13.64%	18.07%	21.11%	19.35%	23.45%
Return on Invested Capital (ROIC)	16.88%	28.65%	25.13%	24.91%	16.37%	18.33%	14.90%	12.65%	12.53%	7.07%	9.68%
ROIC Less NNEP Spread (ROIC-NNEP)	13.59%	21.79%	14.02%	24.07%	15.28%	15.98%	14.60%	11.02%	11.92%	6.16%	8.87%
Return on Net Nonoperating Assets (RNNOA)	2.73%	4.29%	2.53%	3.26%	8.08%	8.14%	7.26%	5.00%	5.91%	2.76%	4.03%
Return on Equity (ROE)	19.61%	32.95%	27.66%	28.17%	24.45%	26.47%	22.16%	17.65%	18.44%	9.83%	13.72%
Cash Return on Invested Capital (CROIC)	-65.85%	-59.12%	-53.76%	-51.19%	4.10%	3.59%	2.84%	0.88%	8.33%	8.00%	8.73%
Operating Return on Assets (OROA)	12.50%	22.33%	15.56%	18.08%	15.12%	12.73%	12.21%	9.39%	11.65%	6.00%	8.86%
Return on Assets (ROA)	9.23%	14.43%	11.61%	14.47%	10.34%	9.90%	9.64%	6.77%	8.28%	4.07%	5.99%
Return on Common Equity (ROCE)	19.61%	32.95%	27.66%	28.17%	24.45%	26.47%	22.16%	17.65%	18.44%	9.83%	13.72%
Return on Equity Simple (ROE_SIMPLE)	17.30%	22.73%	0.00%	23.01%	23.34%	21.67%	0.00%	18.85%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	30	57	48	44	42	48	39	31	33	20	27
NOPAT Margin	20.39%	31.38%	26.88%	25.53%	22.87%	25.30%	20.90%	17.92%	19.08%	10.64%	14.89%
Net Nonoperating Expense Percent (NNEP)	3.29%	6.86%	11.11%	0.84%	1.09%	2.36%	0.30%	1.63%	0.62%	0.91%	0.82%
Return On Investment Capital (ROIC_SIMPLE)	-	-	3.89%	3.46%	-	-	2.92%	2.25%	2.44%	1.47%	1.95%
Cost of Revenue to Revenue	50.08%	39.96%	46.02%	47.57%	47.82%	46.69%	53.55%	50.01%	50.41%	48.58%	53.21%
SG&A Expenses to Revenue	8.43%	7.01%	7.37%	9.12%	7.28%	7.75%	6.94%	9.38%	8.02%	20.57%	9.00%
R&D to Revenue	11.56%	9.23%	11.46%	9.92%	9.68%	11.02%	9.73%	11.78%	11.51%	11.65%	12.73%
Operating Expenses to Revenue	24.60%	19.79%	23.67%	24.49%	21.90%	23.48%	22.25%	28.12%	25.40%	38.22%	27.34%
Earnings before Interest and Taxes (EBIT)	35	76	48	54	56	52	48	35	44	26	36
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	46	95	65	70	72	67	63	51	61	42	53
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.71	3.78	4.63	3.14	2.74	3.25	2.44	1.84	1.43	1.60	1.56
Price to Tangible Book Value (P/TBV)	0.00	0.00	113.41	32.35	17.39	17.78	12.60	8.28	6.05	6.06	5.52
Price to Revenue (P/Rev)	5.13	3.74	4.60	3.12	2.74	3.26	2.44	1.89	1.50	1.71	1.71
Price to Earnings (P/E)	27.21	16.61	21.54	13.65	11.75	14.98	11.19	9.75	8.03	11.10	12.55
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	3.67%	6.02%	4.64%	7.32%	8.51%	6.68%	8.94%	10.25%	12.45%	9.01%	7.97%
Enterprise Value to Invested Capital (EV/IC)	3.37	2.78	3.43	2.50	2.16	2.53	1.96	1.57	1.29	1.42	1.40
Enterprise Value to Revenue (EV/Rev)	5.74	4.29	5.09	3.55	3.24	3.74	2.94	2.38	2.01	2.17	2.16
Enterprise Value to EBITDA (EV/EBITDA)	18.82	11.22	13.32	8.70	7.65	9.86	7.89	6.86	6.00	7.22	7.52
Enterprise Value to EBIT (EV/EBIT)	23.45	13.87	16.98	11.21	9.88	12.89	10.27	9.13	8.14	10.30	11.08
Enterprise Value to NOPAT (EV/NOPAT)	29.82	17.84	20.44	13.46	12.17	14.88	12.42	10.90	9.62	12.73	13.96
Enterprise Value to Operating Cash Flow (EV/OCF)	23.73	14.74	17.87	12.09	10.88	13.00	10.09	9.01	9.11	10.31	9.97
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	56.70	75.59	73.71	190.67	15.88	18.00	16.11
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.85	1.07	0.92	0.88	0.82	0.82	0.82	0.80	0.80	0.78	0.77
Long-Term Debt to Equity	0.83	1.07	0.92	0.88	0.82	0.82	0.82	0.80	0.80	0.78	0.77
Financial Leverage	0.20	0.20	0.18	0.14	0.53	0.51	0.50	0.45	0.50	0.45	0.45
Leverage Ratio	1.93	2.06	1.93	1.92	2.20	2.34	2.25	2.25	2.11	2.13	2.11
Compound Leverage Factor	1.79	1.73	1.65	1.71	1.99	2.14	2.06	1.98	1.90	1.80	1.86
Debt to Total Capital	45.96%	51.76%	47.99%	46.92%	45.15%	45.06%	45.11%	44.57%	44.55%	43.97%	43.62%
Short-Term Debt to Total Capital	1.18%	0.04%	0.04%	0.03%	0.02%	0.02%	0.02%	0.02%	0.07%	0.07%	0.12%
Long-Term Debt to Total Capital	44.78%	51.73%	47.96%	46.89%	45.13%	45.04%	45.09%	44.55%	44.49%	43.90%	43.51%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	54.04%	48.24%	52.01%	53.08%	54.85%	54.95%	54.89%	55.43%	55.45%	56.03%	56.38%
Debt to EBITDA	3.04	2.78	2.40	2.16	1.94	2.17	2.21	2.38	2.51	2.80	2.95
Net Debt to EBITDA	2.01	1.44	1.28	1.04	1.18	1.25	1.34	1.41	1.54	1.52	1.57
Long-Term Debt to EBITDA	2.96	2.78	2.39	2.15	1.94	2.17	2.21	2.38	2.51	2.80	2.94
Debt to NOPAT	4.81	4.42	3.68	3.33	3.09	3.28	3.47	3.78	4.03	4.94	5.48
Net Debt to NOPAT	3.18	2.29	1.97	1.61	1.88	1.89	2.12	2.25	2.46	2.68	2.92
Long-Term Debt to NOPAT	4.69	4.42	3.68	3.33	3.09	3.28	3.47	3.78	4.02	4.93	5.46
Altman Z-Score	3.03	2.53	3.16	2.58	2.85	3.09	2.61	2.27	2.14	2.17	2.32
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.53	2.11	2.17	2.18	3.52	3.43	3.07	2.95	3.29	3.12	4.02
Quick Ratio	1.07	1.62	1.65	1.68	2.55	2.45	2.06	1.92	2.07	2.06	2.70
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-505	-477	-483	-489	-108	-98	-105	-120	-26	-16	12
Operating Cash Flow to CapEx	606.62%	631.16%	252.74%	628.81%	1,143.43%	434.73%	233.86%	327.91%	336.89%	983.23%	397.28%
Free Cash Flow to Firm to Interest Expense	-140.17	-34.82	-51.10	-56.81	-12.50	-14.58	-16.36	-19.08	-4.19	-2.50	1.87
Operating Cash Flow to Interest Expense	15.25	4.70	2.52	6.42	8.03	8.95	4.52	5.58	5.67	8.37	4.96
Operating Cash Flow Less CapEx to Interest Expense	12.73	3.95	1.53	5.40	7.33	6.89	2.59	3.88	3.98	7.52	3.71
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.51	0.53	0.57	0.58	0.50	0.47	0.47	0.46	0.47	0.45	0.45
Accounts Receivable Turnover	5.83	6.13	6.33	5.66	6.04	5.60	5.83	5.17	5.47	5.05	5.14
Inventory Turnover	2.60	2.58	2.80	2.82	2.85	2.83	2.76	2.40	2.31	2.32	2.20
Fixed Asset Turnover	2.10	2.34	2.47	2.54	2.52	2.51	2.52	2.45	2.42	2.39	2.37
Accounts Payable Turnover	1.68	1.73	3.30	3.00	1.85	1.81	2.86	2.47	2.43	2.13	2.38
Days Sales Outstanding (DSO)	62.60	59.51	57.70	64.44	60.45	65.23	62.64	70.62	66.77	72.27	70.95
Days Inventory Outstanding (DIO)	140.24	141.42	130.32	129.50	128.24	128.90	132.28	151.88	158.22	157.58	165.85
Days Payable Outstanding (DPO)	217.38	211.25	110.52	121.49	197.00	201.70	127.62	147.67	149.97	171.46	153.19
Cash Conversion Cycle (CCC)	-14.54	-10.32	77.50	72.45	-8.31	-7.56	67.30	74.83	75.02	58.39	83.60
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	921	925	955	960	1,070	1,071	1,099	1,110	1,130	1,108	1,114
Invested Capital Turnover	0.83	0.91	0.93	0.98	0.72	0.72	0.71	0.71	0.66	0.66	0.65
Increase / (Decrease) in Invested Capital	535	534	531	533	149	146	144	150	60	36	15
Enterprise Value (EV)	3,106	2,577	3,279	2,399	2,313	2,706	2,152	1,740	1,455	1,570	1,556
Market Capitalization	2,774	2,247	2,963	2,112	1,956	2,362	1,785	1,381	1,082	1,239	1,231
Book Value per Share	$12.21	$12.18	$13.35	$13.98	$14.59	$14.95	$15.23	$15.77	$16.07	$16.71	$17.17
Tangible Book Value per Share	($0.75)	($0.50)	$0.55	$1.36	$2.30	$2.73	$2.95	$3.50	$3.80	$4.40	$4.85
Total Capital	1,090	1,234	1,229	1,267	1,300	1,324	1,334	1,355	1,366	1,386	1,399
Total Debt	501	639	590	594	587	597	602	604	609	610	610
Total Long-Term Debt	488	638	590	594	587	596	602	604	608	609	609
Net Debt	332	330	316	287	357	344	367	359	372	331	325
Capital Expenditures (CapEx)	9.05	10	9.44	8.79	6.04	14	12	11	11	5.35	8.27
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-22	-21	5.39	8.35	126	134	136	150	171	157	194
Debt-free Net Working Capital (DFNWC)	146	285	265	300	346	387	361	389	405	435	480
Net Working Capital (NWC)	133	285	264	300	346	387	360	389	404	434	478
Net Nonoperating Expense (NNE)	3.59	7.44	12	0.70	3.76	7.94	1.02	5.27	2.25	3.07	2.83
Net Nonoperating Obligations (NNO)	332	330	316	287	357	344	367	359	372	331	325
Total Depreciation and Amortization (D&A)	10	19	17	16	17	15	15	16	17	17	17
Debt-free, Cash-free Net Working Capital to Revenue	-4.04%	-3.47%	0.84%	1.23%	17.63%	18.56%	18.64%	20.50%	23.68%	21.64%	26.98%
Debt-free Net Working Capital to Revenue	27.03%	47.48%	41.07%	44.41%	48.52%	53.51%	49.26%	53.26%	56.09%	60.16%	66.61%
Net Working Capital to Revenue	24.64%	47.40%	41.00%	44.35%	48.49%	53.48%	49.23%	53.23%	55.96%	60.04%	66.38%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.54	$1.01	$0.76	$0.90	$0.77	$0.83	$0.79	$0.53	$0.66	$0.38	$0.53
Adjusted Weighted Average Basic Shares Outstanding	48.40M	48.70M	48.27M	48.21M	48.91M	48.62M	48.43M	47.64M	46.95M	46.47M	46.74M
Adjusted Diluted Earnings per Share	$0.49	$0.91	$0.70	$0.81	$0.73	$0.78	$0.74	$0.51	$0.64	$0.37	$0.51
Adjusted Weighted Average Diluted Shares Outstanding	53.10M	53.92M	53.00M	53.01M	52.05M	51.86M	52.06M	49.89M	48.13M	47.68M	48.22M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	48.86M	47.91M	48.10M	48.90M	48.68M	48.08M	47.65M	47.14M	46.50M	45.95M	45.37M
Normalized Net Operating Profit after Tax (NOPAT)	30	57	48	44	42	48	39	31	33	20	27
Normalized NOPAT Margin	20.39%	31.38%	26.88%	25.53%	22.87%	25.30%	20.90%	17.92%	19.08%	10.64%	14.89%
Pre Tax Income Margin	22.52%	35.25%	23.21%	27.86%	27.55%	24.94%	23.57%	18.10%	22.55%	11.21%	17.43%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	9.82	5.56	5.13	6.26	6.45	7.76	7.49	5.58	6.96	4.07	5.45
NOPAT to Interest Expense	8.25	4.14	5.06	5.09	4.84	7.22	6.07	4.86	5.30	3.25	4.11
EBIT Less CapEx to Interest Expense	7.31	4.81	4.13	5.24	5.75	5.70	5.55	3.88	5.27	3.22	4.20
NOPAT Less CapEx to Interest Expense	5.74	3.39	4.06	4.07	4.14	5.16	4.14	3.16	3.62	2.40	2.86
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	39.93%	56.33%	42.27%	32.41%	35.13%	27.55%	53.57%	68.11%	94.41%	86.96%	77.05%

Financials Breakdown Chart

Key Financial Trends

Amphastar Pharmaceuticals (AMPH) has shown solid profitability and cash generation in 2025, with some quarterly variability. Here are the most notable takeaways based on the last four quarters and 2025 results.

Q3 2025 revenue reached 191.84M, the strongest quarter in the period, signaling near-term momentum.
Gross margin remained healthy, with Q4 2025 gross margin around 46.7% (gross profit 85.67M on 183.11M revenue), and margins generally in the mid-40s to low-50s in 2025.
Net income remained positive across 2025 quarters (Q1 25.29M, Q2 31.03M, Q3 17.35M, Q4 24.43M), indicating ongoing profitability.
Operating cash flow remained robust, with Q3 2025 at 52.58M and Q4 2025 at 32.86M, showing sustained cash generation from core operations.
Liquidity remained strong, with cash & equivalents around 180–216M during 2025, providing liquidity to fund operations and developments.
Share buybacks in Q4 2025 totaled about 20.5M, a financing move that can support EPS over time by reducing share count.
R&D expense remained meaningful (roughly 12–13% of 2025 revenue), signaling ongoing development that may support future product pipelines.
Debt levels remained stable, with long-term debt around 607–609M and total liabilities in a manageable range, suggesting limited near-term refinancing risk.
Quarterly cash balance pressure emerged in Q4 2025, with net cash from continuing operating activities dipping from Q3’s peak to 32.9M and a negative quarterly change in cash.
Investing cash outflows surged in Q4 2025 (net cash from investing activities about -60.6M), reflecting higher capex and investment activity that weighed on near-term cash balances.

05/05/26 04:48 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Amphastar Pharmaceuticals' Financials

When does Amphastar Pharmaceuticals' financial year end?

According to the most recent income statement we have on file, Amphastar Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

How has Amphastar Pharmaceuticals' net income changed over the last 10 years?

Amphastar Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of $98.09 million in 2025, falling from -$2.79 million in 2015. The previous period was $159.52 million in 2024. See where experts think Amphastar Pharmaceuticals is headed by visiting Amphastar Pharmaceuticals' forecast page.

What is Amphastar Pharmaceuticals' operating income?

Amphastar Pharmaceuticals' total operating income in 2025 was $140.40 million, based on the following breakdown:

Total Gross Profit: $356.06 million
Total Operating Expenses: $215.65 million

How has Amphastar Pharmaceuticals' revenue changed over the last 10 years?

Over the last 10 years, Amphastar Pharmaceuticals' total revenue changed from $251.52 million in 2015 to $719.89 million in 2025, a change of 186.2%.

How much debt does Amphastar Pharmaceuticals have?

Amphastar Pharmaceuticals' total liabilities were at $840.49 million at the end of 2025, a 0.6% decrease from 2024, and a 788.2% increase since 2015.

How much cash does Amphastar Pharmaceuticals have?

In the past 10 years, Amphastar Pharmaceuticals' cash and equivalents has ranged from $65.59 million in 2017 to $170.18 million in 2025, and is currently $170.18 million as of their latest financial filing in 2025.

How has Amphastar Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, Amphastar Pharmaceuticals' book value per share changed from 6.57 in 2015 to 17.17 in 2025, a change of 161.2%.

Related Companies

Financial statements for NASDAQ:AMPH last updated on 3/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amphastar Pharmaceuticals (AMPH) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Amphastar Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amphastar Pharmaceuticals (AMPH) Financials

Annual Income Statements for Amphastar Pharmaceuticals

Quarterly Income Statements for Amphastar Pharmaceuticals

Annual Cash Flow Statements for Amphastar Pharmaceuticals

Quarterly Cash Flow Statements for Amphastar Pharmaceuticals

Annual Balance Sheets for Amphastar Pharmaceuticals

Quarterly Balance Sheets for Amphastar Pharmaceuticals

Annual Metrics And Ratios for Amphastar Pharmaceuticals

Quarterly Metrics And Ratios for Amphastar Pharmaceuticals

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Amphastar Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools